Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. is an Israeli biopharmaceutical company with a platform technology that addresses inflammatory diseases, cancer, and ophthalmic indications currently conducting clinical trials in the U.S., Europe and Israel.[1]
History[edit]
Can-Fite BioPharma Ltd. was founded in 2000 in Israel by current CEO Pnina Fishman, Ph.D., a researcher at the Rabin Medical Center, and Ilan Cohn, Ph.D., a patent attorney and senior partner at Reinhold Cohn Patent Attorneys.[1][2][3]
The company is developing small molecule drugs targeting the A3 adenosine receptor that it licensed from the US National Institutes of Health Office of Technology Transfer invented by Kenneth Jacobson, head of the molecular recognition section of the National Institute of Diabetes & Digestive & Kidney Diseases. Fishman had recognized that cancer does not metastasize to muscle cells, had gone hunting for a factor that muscles might secrete that could resist cancer, and had discovered that muscle cells secrete A3 adenosine receptor agonists.[1] Looking for synthetic A3 agonists, she came across the work of Jacobson, and with Cohn, set up a company to license the patents that the NIH had filed on Jacobson's work. The company is developing these drug candidates as therapeutics for cancer and inflammation.[1][4]
By 2004 Can-Fite had raised $15.7 million in seed and two financing rounds,[3] in October 2005 it went public on the Tel Aviv Stock Exchange,[5]:110 by 2010 it had raised $20 million from venture capital and $30 million from public markets,[6] and in November 2013 it started trading on the New York Stock Exchange.[7]
Subsidiaries[edit]
Can-Fite's subsidiary, OphthaliX Inc.,[8] is a clinical-stage biopharmaceutical company focused on developing therapeutic products for the treatment of ophthalmic disorders.
Development Collaborations[edit]
In 2006, Can-Fite entered into an exclusive Japanese license agreement with Seikagaku Corporation (SKK),[9] a Research and Development-oriented pharmaceutical company. Can-Fite has also signed an exclusive license with Kwang Dong Pharmaceutical Co., Ltd., to distribute CF101 for arthritis in Korea. [9] Can-Fite BioPharma also has a Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH) in the US, and With Leiden University in the Netherlands for patents covering A3AR Agonists.[10]
References[edit]
- ↑ 1.0 1.1 1.2 1.3 LOUËT, Sabine. "Start-up Profiles Can-Fite BioPharma". nature.com. nature publishing group. Retrieved 12 Aug 2014.
- ↑ "Can-Fite Board of Directors". Retrieved 12 Aug 2014.
- ↑ 3.0 3.1 Sabie Louët for Nature Biotechnology. 26 April 2004 Start-up Profiles: Can-Fite Biopharma
- ↑ Aviva Mishmari for Globes. 7 August 2002 Can-Fite fights cancer
- ↑ Can-Fite Form 20-F for 2013
- ↑ Karin Kloosterman for Israel21c. 8 June 2010. A drug discovery boutique
- ↑ Jewish Business News. 3 December 2013. Can-Fite CEO To Ring Opening Bell At New York Stock Exchange
- ↑ "SEC FORM 10-Q for OPHTHALIX INC". U.S. Securities and Exchange Commission. Retrieved 12 Aug 2014.
- ↑ 9.0 9.1 "Can Fite Biopharma Ltd Press Release". NY Times. Retrieved 12 Aug 2014.
- ↑ http://content.stockpr.com/canfite/media/9b05c416dca4f6f4c85706c6867e90f7.pdf
External links[edit]
This article "Can-Fite BioPharma Ltd." is from Wikipedia. The list of its authors can be seen in its historical. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
